Inventiva (NASDAQ:IVA) Sees Large Volume Increase – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-high trading volume on Thursday . 1,355,095 shares were traded during trading, an increase of 192% from the previous session’s volume of 464,733 shares.The stock last traded at $3.5360 and had previously closed at $3.53.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on IVA shares. Truist Financial started coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.56.

Inventiva Stock Performance

The business’s 50-day moving average price is $4.95 and its 200 day moving average price is $5.38.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter. Research analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning acquired a new stake in Inventiva during the 2nd quarter valued at approximately $32,000. Virtu Financial LLC acquired a new position in shares of Inventiva in the 4th quarter valued at approximately $60,000. XTX Topco Ltd purchased a new position in shares of Inventiva during the 4th quarter valued at approximately $84,000. Cerity Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter worth approximately $93,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the third quarter worth approximately $116,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.